Unlocking cancer vaccine potential: What are the key factors? DOI Creative Commons
Michael Grant, Lian Ni Lee, Senthil Chinnakannan

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: April 2, 2024

Cancer is a global health challenge, with changing demographics and lifestyle factors producing an increasing burden worldwide. Screening advancements are enabling earlier diagnoses, but current cancer immunotherapies only induce remission in small proportion of patients come at high cost. vaccines may offer solution to these challenges, they have been mired by poor results past decades. Greater understanding tumor biology, coupled the success vaccine technologies during COVID-19 pandemic, has reinvigorated development. With first signs efficacy being reported, be beginning fulfill their potential. Solid tumors, however, present different hurdles than infectious diseases. Combining insights from previous clinical development contemporary knowledge immunology, we ask: who 'right' patients, what targets, which modalities maximize chances success?

Language: Английский

Hybrid Nanomaterials for Cancer Immunotherapy DOI Creative Commons
Jianing Li,

Wanyue Lu,

Yannan Yang

et al.

Advanced Science, Journal Year: 2022, Volume and Issue: 10(6)

Published: Dec. 25, 2022

Abstract Nano‐immunotherapy has been recognized as a highly promising strategy for cancer treatment in recent decades, which combines nanotechnology and immunotherapy to combat against tumors. Hybrid nanomaterials consisting of at least two constituents with distinct compositions properties, usually organic inorganic, have engineered integrated functions enormous potential boosting immunotherapy. This review provides summary hybrid reported immunotherapy, including nanoscale metal–organic frameworks, metal–phenolic networks, mesoporous organosilica nanoparticles, metallofullerene nanomaterials, polymer–lipid, biomacromolecule‐based nanomaterials. The combination chemotherapy, chemodynamic therapy, radiotherapy, radiodynamic photothermal photodynamic sonodynamic therapy based on is also discussed. Finally, the current challenges prospects designing their application are outlined.

Language: Английский

Citations

72
Engineering nanomaterials for glioblastoma nanovaccination DOI
Fatima Hameedat, Bárbara B. Mendes, João Conniot

et al.

Nature Reviews Materials, Journal Year: 2024, Volume and Issue: 9(9), P. 628 - 642

Published: May 23, 2024

Language: Английский

Citations

17
Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities DOI Creative Commons
Defeng Li,

Qisong Liu,

Meifeng Yang

et al.

Bioengineering & Translational Medicine, Journal Year: 2023, Volume and Issue: 8(3)

Published: Jan. 29, 2023

Abstract Messenger RNA (mRNA) holds great potential in developing immunotherapy, protein replacement, and genome editing. In general, mRNA does not have the risk of being incorporated into host need to enter nucleus for transfection, it can be expressed even nondividing cells. Therefore, mRNA‐based therapeutics provide a promising strategy clinical treatment. However, efficient safe delivery remains crucial constraint application therapeutics. Although stability tolerability enhanced by directly retouching structure, there is still an urgent improve mRNA. Recently, significant progress has been made nanobiotechnology, providing tools nanocarriers. Nano‐drug system used loading, protecting, releasing biological microenvironment stimulate translation develop effective intervention strategies. present review, we summarized concept emerging nanomaterials latest enhancing function mRNA, primarily focusing on role exosomes delivery. Moreover, outlined its applications so far. Finally, key obstacles nanocarriers are emphasized, strategies overcome these proposed. Collectively, nano‐design materials exert functions specific applications, new perception next‐generation nanomaterials, thus revolution technology.

Language: Английский

Citations

38
Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact DOI Creative Commons
Saber İmani, Oya Tagit, Chantal Pichon

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: Jan. 18, 2024

Abstract Recently, chemically synthesized minimal mRNA (CmRNA) has emerged as a promising alternative to in vitro transcribed (IVT-mRNA) for cancer therapy and immunotherapy. CmRNA lacking the untranslated regions polyadenylation exhibits enhanced stability efficiency. Encapsulation of within lipid-polymer hybrid nanoparticles (LPPs) offers an effective approach personalized neoantigen vaccines with improved control over tumor growth. LPP-based delivery systems provide superior pharmacokinetics, stability, lower toxicity compared viral vectors, naked mRNA, or lipid that are commonly used delivery. Precise customization LPPs terms size, surface charge, composition allows optimized cellular uptake, target specificity, immune stimulation. CmRNA-encoded neo-antigens demonstrate high translational efficiency, enabling recognition by CD8 + T cells upon processing presentation. This perspective highlights potential benefits, challenges, future directions Circular RNAs IVT-mRNA. Further research is needed optimize vaccine design, delivery, safety assessment clinical trials. Nevertheless, LPP-CmRNA hold great advancing immunotherapy, paving way medicine.

Language: Английский

Citations

15
Research progress on the quality control of mRNA vaccines DOI Creative Commons
Chaoying Hu, Yu Bai, Jianyang Liu

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 570 - 583

Published: May 11, 2024

The mRNA vaccine technologies have progressed rapidly in recent years. COVID-19 pandemic has accelerated the application of vaccines, with research and development clinical trials underway for many vaccines. Application quality by design (QbD) framework to establishing standardized control protocols vaccines are essential continued high-quality

Language: Английский

Citations

10
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment DOI Creative Commons
Xiaoxue Lang, Xiangtao Wang, Meihua Han

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 4533 - 4568

Published: May 1, 2024

Until now, there has been a lack of effective strategies for cancer treatment. Immunotherapy high potential in treating several cancers but its efficacy is limited as monotherapy. Chemoimmunotherapy (CIT) holds promise to be widely used Therefore, identifying their involvement and synergy CIT approaches decisive. Nano-based drug delivery systems (NDDSs) are ideal because they can simultaneously target immune cells cells, promoting accumulation, reducing the toxicity drug. In this review, we first introduce five current immunotherapies, including checkpoint blocking (ICB), adoptive cell transfer therapy (ACT), vaccines, oncolytic virus (OVT) cytokine therapy. Subsequently, immunomodulatory effects chemotherapy by inducing immunogenic death (ICD), tumor killer infiltration, down-regulating immunosuppressive inhibiting checkpoints have described. Finally, NDDSs-mediated collaborative introduced detail, development nanoparticles prospected.

Language: Английский

Citations

9
mRNA vaccines in the context of cancer treatment: from concept to application DOI Creative Commons
Qiang Fu, Xiaoming Zhao,

Jinxia Hu

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 6, 2025

Immuno-oncology has witnessed remarkable advancements in the past decade, revolutionizing landscape of cancer therapeutics an encouraging manner. Among diverse immunotherapy strategies, mRNA vaccines have ushered a new era for therapeutic management malignant diseases, primarily due to their impressive impact on COVID-19 pandemic. In this comprehensive review, we offer systematic overview vaccines, focusing optimization structural design, crucial role delivery materials, and administration route. Additionally, summarize preclinical studies clinical trials provide valuable insights into current status treatment. Furthermore, delve discussion significant challenges facing development tumor vaccines. These encompass both intrinsic external factors that are closely intertwined with successful application innovative approach. To pave way more promising future treatments, deeper understanding immunological mechanisms, increasing number high-quality trials, well-established manufacturing platform crucial. Collaborative efforts between scientists, clinicians, industry engineers essential achieving these goals.

Language: Английский

Citations

1
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy DOI Creative Commons
Anna De Lucia, L. Mazzotti, Anna Gaimari

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 10, 2025

Over the past decades, significant progress has been made in understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting development novel strategies for early detection wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized treatment landscape NSCLC. Nowadays, remain gold standard many patients, but still they suffer from adverse effects, including unexpected toxicity intrinsic acquired resistance mutations, which lead to relapse. The adoption immune checkpoint (ICIs) 2015, offered exceptional survival benefits patients without targetable alterations. Despite this notable progress, challenges remain, as not all respond favorably ICIs, therapy can develop time. A crucial factor influencing clinical response immunotherapy is microenvironment (TME). TME pivotal orchestrating interactions between neoplastic cells system, growth outcomes. In review, we discuss how intricate relationship success survey current state intervention, a focus on forthcoming promising chimeric antigen receptor (CAR) T sets major obstacles CAR-T therapies, creating conditions that suppress response, inducing exhaustion. To enhance efficacy, specific efforts associated NSCLC, should definitely TME-related immunosuppression escape by combining blockades.

Language: Английский

Citations

1
Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme DOI
Tanvir Ahmed,

Kazi Tasnuva Alam

AAPS PharmSciTech, Journal Year: 2025, Volume and Issue: 26(3)

Published: Feb. 21, 2025

Language: Английский

Citations

1
Plasmid DNA for Therapeutic Applications in Cancer DOI Creative Commons
David Hernán Martínez-Puente, José J. Pérez‐Trujillo, Laura Mireya Zavala-Flores

et al.

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(9), P. 1861 - 1861

Published: Sept. 3, 2022

Recently, the interest in using nucleic acids for therapeutic applications has been increasing. DNA molecules can be manipulated to express a gene of therapy or vaccine development. Plasmid developed treat different diseases, such as infections and cancer. In most cancers, immune system is limited suppressed, allowing cancer cells grow. vaccination demonstrated its capacity stimulate fight against cells. Furthermore, plasmids direct expression proteins with functions, enzymes, toxins, cytotoxic proapoptotic proteins, directly kill The progress promising results reported animal models recent years have led interesting clinical results. These strategies are expected approved treatment near future. This review discusses main strategies, challenges, future perspectives plasmid treatment.

Language: Английский

Citations

38